Quinn Emanuel’s life sciences partners represent pharmaceutical, biotechnology, medical device, and other life sciences companies from around the world. Our life sciences practice is based on an inter-disciplinary model that allows us to become fully familiar with our clients’ businesses and to represent our clients in a wide variety of disputes, including:
• Intellectual Property
• Product Liability
• Government Investigations
• Off-label promotion, and
• Appeals in all subject matters.
Our lawyers know the science. More than 130 of us have degrees in virtually all engineering disciplines and in sciences such as physics, chemistry, pharmacology, molecular biology, biochemistry, and chemical engineering.
We combine this scientific knowledge with first-quality trial skills, making complex subject matter understandable to lay courts and juries. We have a deep bench of highly successful first-chair trial lawyers who work extensively on pharmaceutical and biotechnology patent cases, and other partners with substantial (and successful) experience in product liability cases.
We have won jury verdicts and summary judgment for our life sciences clients at the trial court level. And we have defended these results before appellate courts, including the Federal Circuit and the United States Supreme Court. We have also represented companies before the United States International Trade Commission, arbitration panels, and foreign tribunals.
Our lawyers also have significant experience in cross-border disputes. Many major patent disputes involve lawsuits in both the U.S. and the EU, and over 80% of the patent suits in the EU are filed in Germany. We have German offices in Munich, Hamburg, and Mannheim; each of these offices focuses on intellectual property. Our German and U.S. lawyers work seamlessly to provide our clients with better service, and at a lower price, than would be the case if two firms were involved. Last year JUVE, the leading German legal periodical, named our German offices both “IP Firm of the Year” and “Patent Litigation Firm of the Year.” No non-German firm has ever received either honor. Our U.S. intellectual property group has won similar accolades from The American Lawyer, Benchmark, Law360, and many other publications.
Our lawyers recognize the best result is often a negotiated resolution. While we are a firm of trial lawyers, we recognize that many cases are best served by an early resolution procedure like summary judgment or by vigorous preparation for trial leading to a favorable settlement. We believe our reputation as successful trial lawyers translates into better settlements.
We represented The Broad Institute, Inc. in a patent interference suggested by the University of California and Emmanuelle Charpentier challenging key Broad patents directed to use of CRISPR in eukaryotic cells, humans, other mammals, and plants. We, along with co-counsel, obtained a victory for the Broad, MIT and Harvard as the PTAB declared there was no interference in fact and dismissed the interference with our client's patents. This victory was widely reported in the press, where it was described as "A Knockout in the Biotech Fight of the Century" (Fortune) and "a blow to the University of California" in "a bitterly fought dispute" (NY Times).Back to Top